the this correspondence is being deposited with the United States Postal Service on the date set forth below as First Class envelope addressed to: Mail stop Amendment, Commissioner for Patents, P O Box 1450, Alexandria, VA 22313-1450. Date of Signature and Deposit: August 10, 2006

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Alan D. Attie

Date: August 10, 2006

Jonathan P. Stoehr Kathryn L. Schueler Susanne Michelle Clee

Serial No.: 10/655,915

Group Art Unit: 1634

Filed: 09/05/2003

Examiner: Jehanne Souaya Sitton

Title: TYPE 2 DIABETES SUSCEPTIBILITY GENES

File No.: 960296.99080

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P O Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed are completed PTO-1449 forms listing documents, which the applicants in the above-identified application wish to bring to the attention of the Examiner for consideration in connection with the examination on the merits of this application.

A fee believed to be in the amount of \$180.00 is due in connection with this submission. Please charge the fee to Deposit Account No. 17-0055.

Respectfally submitted,

Sara D. Vinarov

Reg. No. 48,524

Attorney for Applicants **QUARLES & BRADY LLP**

P.O. Box 2113

Madison, WI 53701-2113

00/16/2006 MBERHE 00000013 170055 10655915

TEL 608/251-5000

FAX 608/251-9166

01 FC:1606 180.00 DA

AUG 1 5 2006 the Paperwork Re Substitute ton HOE 49/PTO

Sheet 1

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE ion Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

Complete if Known			
Application Number	10/655,915		
Filing Date	09/05/2003		
First Named Inventor	Alan D. Attie		
Art Unit	1634		
Examiner Name	Jehanne Souaya Sitton		
Attomey Docket Number	960296.99080		

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		US-				
,		US-				
		US-	1			
		US-				
		US-				
		US-	1			
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		üs-				

FOREIGN PATENT DOCUMENTS						
	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
		WO 03/027228 A2	04/03/2003	Incyte Genomics, Inc.		
						<u> </u>

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

AUG 1 5 2006
sperwork Reduction Act of 1865, no persons are

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				e required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known		
				Application Number	10/655,915	
INF	DRMATION	DIS	CLOSURE	Filing Date	09/05/2003	
STATEMENT BY APPLICANT		First Named Inventor	Alan D. Attie			
	(Use as many she	ate se n	acassan/l	Art Unit	1634	
	(ooo as many sno	0.5 45 77		Examiner Name	Jehanne Souaya Sitton	
Sheet	2	of	2	Attorney Docket Number	960296.99080	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Hampe, W, et al., "The genes for the human VPS10 domain-containing receptors are large and contain many small exons," Hum Genet 108:529-536 (2001)	
		Hicke, L., "A New Ticket for Entry into Budding Vesicles-Ubiquitin," Cell 106:527530:1-4 September 7, 2001	
		Kahn, B.B., "Type 2 diabetes: when insulin secretion fails to compensate for insulin resistance, Cell 92:593-496 (1998)	
		Kahn, C.R., et al., "Genetics of non-insulin-dependent (type-II) diabetes mellitus, Annu. Rev. Med. 47:509-531 (1996)	
		Polonsky, K.S., et al, "Non-insulin-dependent diabetes mellitus: a genetically programmed failure of the beta cell, N Engl J Med 334:777-783 (1996)	
		Polonsky, K.S., "The beta-cell in diabetes: from molecular genetics to clinical research, Diabetes 44:705-717 (1995)	
		Stoehr, J.P., et al, "Genetic obesity Unmasks Nonlinear Interactions Between Murine Type 2 Diabetes Susceptibility Loci," Diabetes 49:1946-1954 (2000)	
		Taylor SI: Deconstructing type 2 diabetes Cell 97:9-12 (1999)	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450.

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.